FamiCord announced that it is acquiring Stemlab, positioning it to control the largest cord blood bank in Portugal. To execute the transaction, Polski Bank Komórek Macierzystych S.A. (better known as the Polish Stem Cell Bank or PBKM), a leading company of the global Famicord Group, is acquiring a controlling interest in Stemlab. It will be acquiring 95.6% of the company stock for a purchase price of $16.5M. [Read more…]
Cord Blood
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
Could NiCord® by Gamida Cell Introduce a Paradigm Shift to HSCT?
Gamida Cell is an Israeli company specializing in cellular and immune therapies for the treatment of cancer and orphan genetic diseases. The company is developing a diverse clinical pipeline based on its proprietary NAM technology platform. It lead program, NiCord®, is now in Phase 3 development for allogeneic bone marrow transplantation.
NiCord® was granted Breakthrough Therapy Designation by the FDA, as well orphan drug designation by the European Medicines Agency (EMA). [Read more…]
California Cryobank And CBR Combine To Create A Leading Life Sciences Platform
LOS ANGELES, Aug. 6, 2018 — California Cryobank, the world’s leading donor sperm and donor egg bank, announced today that it has been acquired by GI Partners, a private equity investment firm, from leading healthcare investors Longitude Capital and NovaQuest Capital.
In a separate transaction, GI Partners has also completed its acquisition of Cord Blood Registry (CBR), the world’s largest stem cell collection and storage company, from AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). [Read more…]
Former Stem Cell Patient Announces Foundation’s New Initiative to Guide Stem-Cell Companies, Clinics into FDA “RMAT” Process
Doug Oliver advised Congress on 21st Century Cures Act, leads foundation’s growing network of experts to help clinics pursue FDA approval
“I love what you’re doing and remember those early fateful days where I got you together with Senator Alexander … You reached out to me early on, and with that we’re helping hundreds of thousands, and eventually millions of people through your hard work.”
– Former U.S. Senate Majority Leader Bill Frist, M.D. [Read more…]
Nohla Therapeutics Receives FDA Fast Track Designation for Dilanubicel for Allogeneic Cord Blood Transplant Patients
SEATTLE, Aug. 06, 2018 — Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to dilanubicel (NLA101) for patients with high-risk hematologic malignancies receiving an allogeneic cord blood transplant. Dilanubicel has already received PRIME designation from the European Medicines Agency, and Orphan Drug Designation from the FDA and European Commission. [Read more…]
- « Previous Page
- 1
- …
- 32
- 33
- 34
- 35
- 36
- …
- 62
- Next Page »